Immutep Limited, a late-stage immunotherapy company focused on cancer and autoimmune diseases, has announced an upcoming poster presentation at the IASLC 2025 World Conference on Lung Cancer in Barcelona, Spain. The presentation will detail the pivotal TACTI-004 (KEYNOTE-F91) Phase III trial, which is currently in progress. This trial evaluates the combination of Immutep's antigen presenting cell activator, eftilagimod alfa (efti), with MSD's anti-PD-1 therapy, KEYTRUDA® (pembrolizumab), and chemotherapy as a first-line treatment for patients with advanced or metastatic non-small cell lung cancer. The global trial aims to enroll approximately 750 patients across over 150 clinical sites in more than 25 countries. The results of this study will be presented on Tuesday, 9 September 2025, by Dr. Martin Sebastian from the University Hospital of Frankfurt, Germany.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.